Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAM2038 Opioid Blockade Study
NCT02611752Phase 2Completed
- Sponsor
- Braeburn Pharmaceuticals
- Start
- Oct 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buprenorphine extended-release injection in opioid use disorder (OUD), sponsored by Braeburn Pharmaceuticals. Started Oct 2015; status: completed.
02
Drugs
buprenorphine extended-release injection
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT02611752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02611752.